Statin Use and Risk of Cognitive Decline in the ADNI Cohort

Kemp, Emily C; Ebner, Megan; Ramanan, Srinath; Godek, Tyler A.; Pugh, Erika; Bartlett, Hugh H.; McDonald, Julia W.; Mecca, Marcia C.; Dyck, Christopher H. van; Mecca, Adam P.; Initiative, Alzheimer’s Disease Neuroimaging

doi:10.1016/j.jagp.2019.11.003

Cited by 16 publications

(10 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A preclinical study found that statins were able to reduce Aβ levels in yeast [61], and metaanalyses reported that statins might reduce dementia risk and have beneficial effects on Mini-Mental State Examination scores in AD patients [62,63]. However, other studies and meta-analyses implied that there was insufficient evidence supporting the efficacy of statins in treating AD or lowering AD risk [64][65][66].…”

Section: Lipid Metabolism Regulatorsmentioning

confidence: 99%

New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease

et al. 2020

View full text Add to dashboard Cite

As the population ages, Alzheimer's disease (AD), the most common neurodegenerative disease in elderly people, will impose social and economic burdens to the world. Currently approved drugs for the treatment of AD including cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) and an N-methyl-D-aspartic acid receptor antagonist (memantine) are symptomatic but poorly affect the progression of the disease. In recent decades, the concept of amyloid-β (Aβ) cascade and tau hyperphosphorylation leading to AD has dominated AD drug development. However, pharmacotherapies targeting Aβ and tau have limited success. It is generally believed that AD is caused by multiple pathological processes resulting from Aβ abnormality, tau phosphorylation, neuroinflammation, neurotransmitter dysregulation, and oxidative stress. In this review we updated the recent development of new therapeutics that regulate neurotransmitters, inflammation, lipid metabolism, autophagy, microbiota, circadian rhythm, and disease-modified genes for AD in preclinical research and clinical trials. It is to emphasize the importance of early diagnosis and multiple-target intervention, which may provide a promising outcome for AD treatment.

show abstract

Section: Lipid Metabolism Regulatorsmentioning

confidence: 99%

New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Previous studies were also limited by their retrospective design, heterogeneous patient populations, type of statin and dosage,and definition of memory impairment. 8 , 9 In this study, we addressed some of these limitations by recruiting a relatively homogenous population, with no baseline memory impairment, and used fixed-dose of atorvastatin.…”

Section: Discussionmentioning

confidence: 99%

Is the use of high-intensity atorvastatin associated with memory impairment?

Kidambi¹,

Purohit

Bajpai

et al. 2022

Indian Heart Journal

View full text Add to dashboard Cite

“…In addition, previous studies found statin use could be protective for patients with mild cognitive impairment (MCI). 38 , 39 However, patients with MCI were less likely to be captured in claim-based data. Thus, a misclassification bias could still exist.…”

Section: Discussionmentioning

confidence: 99%

Adherence to Statins Use and Risk of Dementia among Patients with Diabetes and Comorbid Hyperlipidemia

Chang

Lin

Hong

et al. 2021

INQUIRY

View full text Add to dashboard Cite

The results from previous observational studies and clinical trials about the neuroprotective benefits of statins use for the prevention of dementia are contradictory. It is unclear whether the neuroprotective benefits are experienced in a specific group with a higher risk of dementia, such as patients with concurrent diabetes and hyperlipidemia. We aimed to examine the association between adherence to statins and the risk of dementia among patients with diabetes and comorbid hyperlipidemia. This was a retrospective study with a new user design. We used data from the Taiwan National Health Insurance Research Database to identify patients with diabetes and comorbid hyperlipidemia. The occurrence of dementia was the study outcome. The adherence to statins was the exposure, which was measured by the proportion of days covered (PDC) of statins. The good adherence included patients with ≥80% PDC of statins. Cox proportional hazards regression models were used to evaluate the association between adherence to statins and dementia. Among 18,125 included individuals with diabetes and comorbid hyperlipidemia, 33.5% had good adherence to statins. Compared to poor adherence to statins, good adherence to statins was not significantly associated with a reduced risk of dementia (hazard ratio = 0.94; 95%confidence interval = 0.70–1.24) among patients with diabetes and comorbid hyperlipidemia. Good adherence to statins was not found to be associated with the risk of dementia among patients with diabetes and comorbid hyperlipidemia in Taiwan. Future studies with a more diverse study population are needed to evaluate the neuroprotective effects of statins use on dementia prevention.

show abstract

Statin Use and Risk of Cognitive Decline in the ADNI Cohort

Cited by 16 publications

References 28 publications

New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease

New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease

Is the use of high-intensity atorvastatin associated with memory impairment?

Adherence to Statins Use and Risk of Dementia among Patients with Diabetes and Comorbid Hyperlipidemia

Contact Info

Product

Resources

About